The FDA is expected to decide on treatments for breast cancer, EBV+ post-transplant lymphoproliferative disease, focal segmental glomerulosclerosis, presbyopia, and severe allergic reactions.
Treatment with deramiocel led to a 54% slowing of upper limb function deterioration and a 91% slowing of cardiac function deterioration compared with placebo. Topline data were announced from a phase ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback